International Journal of
ADVANCED RESEARCH & INNOVATIONS

Volume 13, Issue-12
December, 2023, P08
ISSN: 2319-9253

ARTIFICIAL INTELLIGENCE FOR PRECISION CANCER PREVENTION: PREDICTIVE ANALYTICS, RISK STRATIFICATION, AND EARLY INTERVENTION

[#1]**Dr. Keshav Prasad,** Professor, Department of Radiation Oncology,
Apollo Institute of Medical Sciences and Research, Hyderabad, India
Keshavprasad83@gmail.com

[#2]**Dr. Sonia Kapoor,** Associate Professor, Department of Pharmacology,
Apollo Institute of Medical Sciences and Research, Hyderabad, India
Soniakapoor41@gmail.com

[#3]**Dr. Abhinav Reddy,** Assistant Professor, Department of Pathology,
Apollo Institute of Medical Sciences and Research, Hyderabad, India
Abhinavreddy58@gmail.com

Abstract: Artificial intelligence (AI) is transforming cancer prevention by enabling precision risk prediction, individualized screening, early disease detection, and personalized preventive interventions through comprehensive integration of multimodal biomedical data. Conventional cancer prevention strategies primarily rely on population-level risk estimates based on age, family history, environmental exposures, and lifestyle factors, often failing to capture the complex biological heterogeneity underlying cancer susceptibility and disease initiation. Recent advances in foundation AI models, multimodal transformer architectures, graph neural networks, self-supervised learning, reinforcement learning, and generative artificial intelligence have enabled integration of radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, microbiomics, spatial biology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, environmental exposures, electronic health records, digital biomarkers, and longitudinal clinical outcomes into unified computational representations of cancer risk. These intelligent systems support individualized risk stratification, biomarker discovery, personalized screening, early cancer detection, behavioral intervention, chemoprevention, lifestyle optimization, and evidence-based clinical decision support. Emerging technologies including multimodal large language models, federated learning, retrieval-augmented generation, explainable artificial intelligence, agentic AI, digital twins, cloud-native healthcare platforms, and digital health ecosystems further strengthen preventive oncology by enabling collaborative, privacy-preserving, transparent, and continuously adaptive biomedical intelligence. Despite remarkable technological progress, important scientific, technical, ethical, and regulatory challenges remain regarding multimodal data harmonization, computational scalability, interoperability, cybersecurity, clinical validation, regulatory acceptance, and equitable implementation. This review provides a comprehensive overview of artificial intelligence for precision cancer prevention, emphasizing predictive analytics, risk stratification, and early intervention as transformative approaches for next-generation preventive oncology.[1]

Keywords: *Precision cancer prevention, Artificial intelligence, Foundation models, Predictive analytics, Risk stratification, Early intervention, Precision oncology, Digital health, Computational oncology, Personalized medicine.*

Paper Available at: *www.ijarai.com*
DOI : https://doi.org/10.65713/ijaraiv13i1208

1. Introduction

Cancer prevention represents one of the most effective strategies for reducing cancer incidence, mortality, healthcare costs, and global disease burden. Although remarkable advances have been achieved in cancer diagnosis and treatment, a substantial proportion of malignancies remain preventable through identification of high-risk individuals, early disease detection, modification of environmental and behavioral risk factors, vaccination, chemoprevention, and personalized surveillance. However, conventional prevention strategies frequently rely on generalized population-level recommendations that inadequately capture individual biological variability and evolving cancer susceptibility.[2]

Modern biomedical research generates enormous quantities of heterogeneous information through radiological imaging, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, microbiome profiling, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, environmental exposure assessment, physician documentation, electronic health records, biomedical literature, and patient-reported outcomes. Although each modality contributes valuable insight into cancer risk, isolated interpretation frequently limits comprehensive understanding of disease initiation and progression.[3]

Artificial intelligence provides a transformative computational framework capable of integrating these diverse biomedical datasets into unified patient-specific representations that support individualized cancer risk assessment, personalized screening strategies, early detection, and precision preventive interventions.

2. Evolution of Artificial Intelligence in Cancer Prevention

Cancer prevention has evolved from generalized public health recommendations toward precision prevention strategies driven by molecular biology and computational intelligence. Early prevention models primarily relied upon epidemiological observations associating lifestyle factors, environmental exposures, inherited susceptibility, and demographic characteristics with cancer incidence. While these models provided valuable population-level guidance, they lacked sufficient precision for individualized preventive medicine.[4]

Machine learning subsequently enabled analysis of large epidemiological datasets and clinical registries, improving individualized risk estimation. Deep learning further expanded computational capabilities through automated analysis of radiological imaging, pathology, genomics, and electronic health records.

Foundation AI models now acquire generalized biomedical knowledge through large-scale multimodal self-supervised learning, enabling comprehensive characterization of cancer susceptibility, biomarker discovery, adaptive screening, behavioral intervention, and continuously personalized preventive oncology.[5]

3. Principles of Foundation AI Models for Cancer Prevention

Foundation AI models differ fundamentally from conventional predictive algorithms because they acquire transferable biomedical representations from massive multimodal datasets before specialization for specific preventive applications. Rather than learning isolated prediction tasks, these models develop generalized computational knowledge applicable across cancer risk assessment, biomarker discovery, early diagnosis, preventive therapeutics, behavioral intervention, population health, and clinical decision support.[6]

Self-supervised learning enables discovery of latent biological relationships without requiring extensive manual annotation, while multimodal transformer architectures align radiological imaging, genomics, transcriptomics, proteomics, metabolomics, epigenomics, microbiomics, wearable physiological monitoring, environmental exposure data, physician documentation, patient-reported outcomes, biomedical literature, and longitudinal clinical trajectories within unified computational embedding spaces.

Graph neural networks further characterize interactions among genes, proteins, metabolites, signaling pathways, immune populations, environmental exposures, behavioral factors, physiological variables, and clinical outcomes, enabling systems-level computational reasoning throughout preventive oncology.[7]

Volume 13, Issue-12
December, 2023, P08
ISSN: 2319-9253

4. Computational Architecture

Modern AI-driven precision prevention platforms consist of interconnected computational layers responsible for biomedical data acquisition, preprocessing, multimodal representation learning, predictive analytics, adaptive inference, digital twin simulation, risk modeling, and intelligent clinical decision support.[8]

The acquisition layer continuously integrates radiological imaging, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, microbiome profiling, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, environmental exposures, biomedical literature, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, synchronize longitudinal patient information, and continuously incorporate evolving scientific evidence.

Foundation AI models subsequently generate generalized multimodal embeddings representing inherited susceptibility, molecular biology, physiological function, environmental exposures, behavioral characteristics, and longitudinal health trajectories supporting precision cancer prevention.[9]

5. Predictive Analytics for Cancer Risk Assessment

Predictive analytics represents one of the most important applications of artificial intelligence in preventive oncology by estimating individualized cancer risk before clinical disease develops. Foundation AI models integrate demographic characteristics, family history, inherited genetic susceptibility, radiological imaging, laboratory biomarkers, genomics, transcriptomics, proteomics, metabolomics, environmental exposures, lifestyle factors, wearable physiological monitoring, and longitudinal clinical information to generate continuously updated individualized risk profiles.[10]

Transformer architectures identify subtle nonlinear relationships among inherited susceptibility, environmental exposures, metabolic regulation, immune function, behavioral characteristics, and physiological adaptation that frequently remain undetected by conventional statistical approaches. Self-supervised learning further enables identification of novel predictive biomarkers without requiring manually annotated datasets.

These computational approaches substantially improve individualized cancer prediction, screening optimization, preventive intervention, and personalized surveillance.[11]

6. Artificial Intelligence for Risk Stratification

Risk stratification enables clinicians to classify individuals into biologically meaningful risk categories according to comprehensive integration of multimodal biomedical information. Foundation AI models evaluate molecular biomarkers, inherited pathogenic variants, radiological imaging phenotypes, metabolic characteristics, immune responses, environmental exposures, physiological monitoring, laboratory investigations, and behavioral information to generate adaptive risk classifications that continuously evolve throughout the patient's lifetime.[12]

Graph neural networks characterize complex interactions among genes, signaling pathways, immune regulation, environmental carcinogens, microbiome composition, physiological adaptation, and lifestyle behaviors while transformer architectures integrate heterogeneous biomedical modalities into unified computational representations.

These adaptive risk models substantially improve screening prioritization, surveillance scheduling, preventive counseling, and allocation of healthcare resources while supporting equitable precision prevention strategies.[13]

7. Biomarker Discovery for Early Detection

Identification of highly sensitive biomarkers capable of detecting cancer during its earliest biological stages represents one of the greatest opportunities for artificial intelligence. Foundation AI models integrate genomics, transcriptomics, proteomics, metabolomics, epigenomics, circulating tumor DNA, circulating tumor cells, extracellular vesicles, microbiome profiles, radiological imaging, laboratory biomarkers, and physiological monitoring into generalized

Paper Available at: *www.ijarai.com*
DOI : https://doi.org/10.65713/ijaraiv13i1208

molecular representations capable of identifying early biological signatures associated with malignant transformation.[14]

Artificial intelligence identifies latent relationships among genes, proteins, metabolites, signaling pathways, immune responses, and imaging phenotypes while continuously refining biomarker performance through self-supervised learning and real-world clinical evidence.

These integrated biomarker representations substantially improve early diagnosis, population screening, prognostic prediction, personalized surveillance, and translational cancer prevention research.[15]

8. Personalized Screening and Early Intervention

Artificial intelligence enables individualized screening strategies that extend beyond conventional age-based recommendations by continuously integrating inherited susceptibility, molecular biomarkers, imaging phenotypes, environmental exposures, physiological monitoring, behavioral information, and longitudinal clinical trajectories. Rather than applying uniform screening schedules, foundation AI models dynamically optimize screening intervals, imaging modalities, laboratory investigations, and preventive interventions according to continuously evolving patient-specific risk.[16]

Digital health technologies, wearable biosensors, mobile health applications, and remote physiological monitoring further support continuous surveillance while promoting behavioral modification, medication adherence, lifestyle optimization, smoking cessation, dietary improvement, physical activity, and early clinical intervention.

These adaptive screening ecosystems improve early cancer detection, reduce unnecessary investigations, optimize healthcare resource utilization, and strengthen precision prevention.[17]

9. Digital Health and Continuous Preventive Monitoring

Digital health technologies have become indispensable components of precision cancer prevention by continuously collecting longitudinal physiological, behavioral, and environmental information outside traditional healthcare settings. Wearable biosensors, smart medical devices, mobile health platforms, Internet of Medical Things (IoMT) ecosystems, and patient-reported outcomes provide real-time measurements of physical activity, sleep quality, cardiovascular function, metabolic health, medication adherence, environmental exposure, stress, and quality of life. Foundation AI models integrate these digital biomarkers with molecular biology, radiological imaging, laboratory investigations, electronic health records, and environmental information to generate adaptive preventive intelligence capable of identifying subtle biological changes associated with increasing cancer risk while continuously recommending individualized preventive interventions. These intelligent digital ecosystems establish the computational foundation for proactive, continuously personalized, and evidence-based cancer prevention throughout the lifespan.[18][19][20]

10. Digital Twins for Preventive Oncology

Digital twin technology represents one of the most transformative applications of artificial intelligence in precision cancer prevention by creating continuously evolving virtual representations of individual health trajectories before clinical disease develops. Foundation AI models integrate serial radiological imaging, genomics, transcriptomics, proteomics, metabolomics, epigenomics, microbiome profiles, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, environmental exposures, lifestyle characteristics, medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating future cancer risk, disease initiation, progression, therapeutic responsiveness, and long-term health outcomes.[21]

Unlike conventional predictive models based upon static baseline measurements, preventive digital twins continuously update their computational representations as new biological, physiological, behavioral, and environmental information becomes available. Integration of multimodal molecular biology with predictive simulation enables clinicians to evaluate multiple preventive interventions before disease develops, optimize surveillance strategies, estimate the long-term effects of lifestyle modification, and personalize chemoprevention according to continuously evolving patient biology.

By combining multimodal biomedical intelligence with predictive simulation, digital twins transform cancer prevention from reactive disease management toward proactive, continuously adaptive, and individualized preventive medicine.

11. Intelligent Clinical Decision Support

Foundation AI models provide the computational infrastructure for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered preventive recommendations. Rather than interpreting radiological imaging, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, environmental exposures, and evidence-based clinical guidelines independently, these models synthesize diverse biomedical information into unified computational representations supporting preventive oncology practice.[22]

Interactive clinical dashboards generate individualized cancer risk summaries, molecular biomarker analyses, hereditary susceptibility profiles, environmental exposure assessments, digital twin simulations, preventive recommendations, screening schedules, surveillance strategies, behavioral interventions, chemoprevention guidance, and long-term outcome predictions while facilitating collaboration among oncologists, primary care physicians, radiologists, genetic counselors, epidemiologists, nutritionists, behavioral scientists, public health specialists, pharmacists, nurses, and computational scientists.

These intelligent systems improve workflow efficiency, strengthen multidisciplinary communication, reduce fragmentation of biomedical information, and promote evidence-based personalized cancer prevention.

12. Continuous Learning and Adaptive Prevention

A defining characteristic of artificial intelligence–enabled precision prevention is the ability to continuously evolve as new biomedical information becomes available. Artificial intelligence incorporates serial imaging examinations, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication adherence, behavioral information, patient-reported outcomes, environmental exposure data, biomedical literature, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining predictive accuracy throughout an individual's lifetime.[23]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes screening strategies, preventive interventions, and surveillance recommendations through iterative evaluation of longitudinal health outcomes. Consequently, preventive oncology platforms remain synchronized with evolving biological risk, physiological adaptation, environmental exposures, emerging scientific discoveries, changing clinical guidelines, and diverse population characteristics.

This adaptive computational paradigm transforms preventive oncology into a continuously learning healthcare ecosystem capable of supporting real-time personalized cancer prevention.

13. Federated Prevention Intelligence Networks

Development of highly generalizable foundation AI models for precision prevention requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, genomic technologies, laboratory networks, wearable ecosystems, environmental conditions, and patient populations. Federated learning enables collaborative development of foundation AI models while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local models using radiological imaging, genomics, transcriptomics, laboratory investigations, wearable monitoring, environmental exposure assessments, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, transparency, and generalizability across diverse healthcare environments.

Federated preventive intelligence ecosystems therefore establish international collaborative research networks capable of accelerating scientific discovery, improving equitable access to precision prevention, and supporting global cancer control while maintaining responsible biomedical data stewardship.

14. Explainability, Validation, and Ethical Governance

Successful implementation of artificial intelligence in precision cancer prevention requires transparent, interpretable, reproducible, and rigorously validated computational systems capable of supporting clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence (XAI) enables clinicians to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, multimodal attention mapping, and counterfactual explanations identifying the genetic, molecular, physiological, behavioral, environmental, and clinical variables responsible for individualized risk predictions.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, transparent reporting standards, and compliance with evolving international regulatory frameworks governing AI-enabled preventive healthcare technologies.

Responsible implementation further depends upon patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, continuous post-deployment surveillance, and multidisciplinary oversight to ensure trustworthy integration of artificial intelligence into routine preventive oncology practice.

15. Future Perspectives

Future precision prevention ecosystems will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, single-cell sequencing, liquid biopsy, quantum computing, Internet of Medical Things (IoMT), robotics, cloud-native healthcare infrastructure, and autonomous preventive reasoning systems into unified cancer prevention platforms.[26]

These next-generation computational ecosystems will continuously integrate molecular biology, radiological imaging, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, behavioral science, pharmacological knowledge bases, and real-world health outcomes while autonomously coordinating personalized screening, lifestyle optimization, vaccination strategies, chemoprevention, behavioral counseling, and continuous evidence synthesis.

Such intelligent preventive ecosystems are expected to transform oncology from generalized population-based prevention toward predictive, preventive, adaptive, continuously learning, and precision-guided healthcare across the global population.

16. Discussion

Artificial intelligence–enabled precision cancer prevention represents one of the most significant paradigm shifts in preventive medicine by integrating predictive analytics, molecular biology, digital biomarkers, digital twins, wearable technologies, environmental science, behavioral health, and foundation AI models into unified computational ecosystems capable of supporting individualized cancer prevention. Unlike conventional prevention strategies based upon generalized risk estimates, intelligent preventive platforms continuously analyze evolving biological, physiological, environmental, behavioral, and clinical information to generate adaptive patient-specific recommendations.[27]

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv13i1208

Applications spanning inherited cancer risk prediction, radiological screening, molecular biomarker discovery, liquid biopsy, digital twins, behavioral intervention, chemoprevention, digital health, continuous learning, federated collaboration, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of foundation AI models to redefine preventive oncology. Nevertheless, successful implementation requires continued advances in multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, artificial intelligence is expected to become one of the foundational computational infrastructures supporting precision cancer prevention worldwide.

17. Conclusion

Artificial intelligence is transforming precision cancer prevention by integrating predictive analytics, radiological imaging, multi-omics, laboratory biomarkers, wearable technologies, environmental exposure assessment, electronic health records, digital biomarkers, digital twins, and longitudinal clinical intelligence into unified computational ecosystems capable of supporting individualized risk prediction, biomarker discovery, adaptive screening, personalized surveillance, early intervention, and evidence-based preventive medicine throughout the lifespan.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen intelligent preventive ecosystems, enabling increasingly accurate cancer risk prediction, adaptive screening strategies, continuous health monitoring, personalized preventive interventions, and precision public health.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, primary care physicians, epidemiologists, radiologists, genetic counselors, molecular biologists, biomedical engineers, computer scientists, public health organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of artificial intelligence in preventive oncology. These innovations have the potential to reduce cancer incidence, improve population health, enhance healthcare efficiency, reduce disparities in cancer prevention, accelerate translational research, and establish a new era of intelligent, adaptive, and continuously learning precision cancer prevention worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.

3. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.

4. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881

5. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.

6. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

7. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol.

51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
8. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
9. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
10. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
11. Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.
12. Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.
13. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
14. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
15. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
16. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
17. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
18. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
19. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
20. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
21. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
22. Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.
23. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
24. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
25. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
26. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
27. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
28. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
29. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
30. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.